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Introduction 
Chronic renal failure (CRF) is a worldwide public health problem that is associated with 
a high risk of occurrence of cardiovascular events [9,19]. Hemodialysis (HD) is performed in 
more than 90% of patients in advanced stages of CRF. The number of HD patients in Japan 
has increased from 1624.1 per million at the end of 2000 to 2279.5 per million in 2009. The 
total number of HD patients exceeded 281,996 in 2009, the highest rate since 1983 [17]. The 
trend is similar in other countries, the total number of HD patients in the United States 
increasing from 281,355 in 2000 to 415,013 in 2010 (United States Renal Data System) 
[4,26]. Several studies have indicated that the incidence of ischemic and hemorrhagic 
events in the intracranial region (strokes) in CRF patients is high [1,7,8,10,12,14- 
16,18,21-23,27]. A single-center study in Japan showed that the frequency of intracerebral 
hemorrhage (ICH, 52% of 151 patients) in HD patients was higher than that of cerebral 
infarction (CI, 41%) between 1980 and 1996, while the rate of ICH (29%) between 1997 and 
2002 was lower than that of CI (68%) [23]. Intensive control of hypertension, diabetes and 
hyperlipidemia may have reduced the incidence of ICH. However, the clinical status of HD 
patients with ICH remains severe, ICH being a common cause of death in HD patients. The 
incidence of death due to ICH is 2- to 3-fold higher than that due to CI [8,10,12,15].  
Here, we retrospectively investigated 5 years worth of clinical data from ICH patients 
treated with or without HD at our institution. We reveal the differences in the clinical courses 
of HD and non-HD patients and identify the risk factors for poor outcomes in ICH patients 
undergoing HD.  
 
 
Patients and Methods 
We conducted a single-center retrospective study based upon a review of medical records. 
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The records of 366 consecutive patients with non-traumatic spontaneous ICH who were 
admitted to the neurosurgical department of Hitachi General Hospital between January 2007 
and December 2011 were examined. Patients with ICH due to secondary causes, such as 
ruptured aneurysm, primary ischemic stroke, and arteriovenous malformation or tumor, were 
excluded from this study. In all cases, computed tomography (CT) scan was performed on 
admission. Magnetic resonance imaging (MRI) was performed on admission or after surgery 
for all patients with ICH except for deceased patients whose condition was rapidly 
deteriorating.  
The following clinical information, including baseline characteristics, was collected: age, 
gender, location/side of the hematoma, volume of the hematoma, presence of 
intraventricular hemorrhage (IVH), microbleeds (MBs) on MRI scans, modified Rankin scale 
(mRS) scores at admission/discharge, type of surgical operation, use of antihypertensive 
and anti-diabetic drugs and antiplatelets/anticoagulants, primary renal disease, current 
history of HD, and the day of the week on which the ICH occurred in relation to HD. The 
hematoma volume in each case was determined by one of the authors (N.S.) from CT scans 
obtained at the onset as follows: the maximum transverse diameter × the maximal 
antero-posterior diameter × the maximal supero-inferior diameter × 1/2. Presence of IVH 
was also assessed using CT scans. Hematoma volume in the lateral ventricle was not 
included in the calculation of ‘volume of hematoma’ in this study. 
The values are expressed as means ± SD. Differences in patient data were evaluated 
using univariate logistic analysis as well as χ2 test, Fisher’s test or Student t test. P values 
less than 0.05 were considered to indicate statistical significance. All calculations were 
performed using JMP 5 software (SAA Corp., USA). Multivariate logistic analysis was 
performed for data in which p values were less than 0.1 on univariate logistic analyses. 
Differences were considered statistically significant if the p value was <0.05 in this analysis 
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as well. In the logistic analyses, continuous variables were dichotomized in terms of their 
mean or median values. 
 
 
Results 
Comparisons between HD and non-HD patients   
Table 1 shows the clinical characteristics of the patients in the study. A total of 366 patients 
were admitted to our hospital with a diagnosis of ICH during the study period. They were 
divided into two groups: 32 patients (9%) with CRF who received HD (HD group) and 334 
patients who did not receive HD treatment (non-HD group). All the CRF patients in this study 
were on HD. Surgical hematoma evacuation was performed in 25% of the HD patients and in 
13.5% of the non-HD patients, while a hematoma drain was inserted into the lateral ventricle 
of 6% and 7.5% of HD and non-HD patients, respectively. There were no differences in 
patient age, gender, laterality of hematoma and surgical procedure between the two groups. 
The HD group had higher rates of hematomas in the basal ganglia (84% in the HD group vs. 
57% in the non-HD group, p<0.05), IVH (53% vs. 34%, p<0.05), use of antihypertensive 
drugs (72% vs. 32%, p<0.01), use of anti-diabetic drugs (41% vs. 20%, p<0.01) and use of 
antiplatelets/anticoagulants (41% vs. 17%, p<0.01). The mortality rate (mRS VI) was higher 
in the HD group (44%) than in the non-HD group (21%). There were no significant 
differences in the existence of cerebral MBs between the two groups, as seen on MRI (p>0.1, 
Fisher direct test). As seen in Table 1, univariate logistic analysis showed that hematoma 
location, presence of IVH, use of antihypertensive drugs, use of anti-diabetic drugs, use of 
antiplatelets/anticoagulants, patient mortality, and the number of patients with mRS ≥5 were 
significantly different between HD and non-HD groups. Similar results were also shown 
using the χ2 test or Fisher’s test (data not shown). Multivariate logistic analysis showed that 
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hematoma location, use of antihypertensive drugs, use of antiplatelets/anticoagulants, and 
number of patients with mRS ≥5 were different between the two groups (Table 1). 
Analysis of patients who had died (mRS VI) in both groups indicated significant differences 
in the number of hematomas in the basal ganglia (86% vs. 45%, p<0.01), the use of 
antihypertensive drugs (50% vs. 21%: p<0.01) and the use of antiplatelets/anticoagulants 
(36% vs. 12%, p<0.05). There were no significant differences in the use of anti-diabetic 
drugs and incidence of IVH between the two groups.  
 
Analyses of HD patients   
Next, detailed data from the 32 patients on HD was analyzed. The causes of CRF were 
diabetic nephropathy (44%), glomerulonephritis (19%), cystic kidney disease (3%), sclerosis 
(3%), renal carcinoma (3%) and unknown etiology (28%). On admission, 13 patients (41%) 
received antiplatelets/anticoagulants for maintenance of shunt patency (31.2%), history of 
previous angina pectoris (2 cases), or history of previous cerebral infarction (1 case). 
The condition of 24 of the patients (75%) was rated as being serious (mRS V) at the time 
of hospitalization, and antihypertensive drugs were administered to 23 of these patients. 
Mean systolic blood pressure values on admission in patients with and without 
antihypertensive drugs before admission were 190.0+/-43.2 and 166.3+/-53.1 mmHg 
(p>0.05, Student t test), respectively. Hematoma drain placement in the lateral ventricle was 
performed in 2 patients, both of who survived, while surgical hematoma evacuation was 
performed for 6 patients who survived and 2 patients who had a poor outcome (mRS VI). 
The final outcomes were mRS VI (44%) and V (25%). As shown in Figure 1, most patients’ 
conditions did not improve throughout hospitalization. We analyzed the risk factors for poor 
outcomes (mRS VI). As shown in Table 2, univariate logistic analysis demonstrated 
significant differences between the patients who did and did not survive in terms of GCS 
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scores on admission, mRS scores on admission, hematoma volume, presence of IVH, and 
the use of antihypertensive drugs. Multivariate logistic analysis, however, showed no 
significant prognostic factor, indicating that the results of the analysis should only be used as 
an advisory, since the analyses were performed in a small sized sample. Older patients 
tended to have higher mortality rates than younger patients, although the difference between 
the two groups was not significant. There was no difference in systolic blood pressure 
between poor outcome patients and other HD patients (179.8+/- 59.8 mmHg (n=13) vs. 
185.0+/- 35.0 (n=16), p>0.1, Student t test), or in HD duration between poor outcome 
patients and other HD patients (7.1 +/- 5.4 years (n=13) vs. 7.7 +/- 4.3 (n=15), p>0.1, 
Student t test).  
As shown in Figure 2, no significant difference was observed between mortality (mRS VI) 
due to ICH on dialysis days (10 cases, 37%) and non-dialysis days (17 cases, 63%) in 27 
cases with data regarding the timing of the ICH (p>0.05, Fisher’s method). In these cases, 
26% of the ICH occurred before the HD procedure on an HD day, which was a higher rate 
than during or after the HD procedure (11%) on the dialysis day. 
 
 
Discussion  
On admission, the condition of ICH patients on HD in this study was frequently classified 
as being serious. The prognostic factors associated with mortality were GCS on admission 
<8, hematoma volume >50 ml, the presence of IVH, and lack of antihypertensive drug usage. 
In previous papers, the overall 30-day mortality rate in ICH patients with advanced CRF has 
been shown to be 30 - 83% [7,16]. In one of the studies, the prognostic factors 
independently associated with mortality were as follows: GCS scores, old age, systolic blood 
pressure, ICH volume ≥30 ml, presence of IVH, and high serum glucose [7]. In another 
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paper, additional factors indicating poor prognosis were level of consciousness on admission, 
the size and shape of the hematoma, prothrombin time, and fibrin degradation product level 
[14]. In general, cerebral MBs detected on T2-weighted MRI scans are closely related to ICH 
[11,13,20,24], although our results could not corroborate this since our data included only 
ICH patients. A previous paper showed that 35% of CRF patients had MBs. Factors 
associated with MBs were male sex, old age, hypertension and worsening of CRF, although 
MBs did not show a correlation with the duration of HD treatment [25].  
In our study, antihypertensive drugs were used more frequently by CRF patients than 
non-CRF patients. CRF patients frequently have renal hypertension, which may cause ICH. 
The odds ratio for ICH was 2.44 in the CRF group when compared to the non-CRF group 
[22]. However, the use of antiplatelets/anticoagulants did not significantly predict poorer 
outcomes. Therefore, patients should strictly control their hypertension and should not 
hesitate to take antiplatelets/anticoagulants as they do not pose a risk for ICH. A limitation of 
the present study is that the results were obtained from retrospective and non-controlled 
data. However, various analyses, including univariate and multivariate logistic regression 
analyses showed similar results. Hence, we believe that these results are generally reliable. 
 
As shown in Figure 2, ICH frequently occurred on a non-dialysis day. HD in CRF 
patients is usually scheduled three times a week, and some reports show that the 
occurrence of disease is related to the day of HD. For example, sudden cardiac death 
events occur more often on Mondays and Wednesdays [2]. The occurrence rates of acute 
myocardial infarction, heart failure and stroke are high when the interval between HD 
treatments is two days [5], This suggests that medical practitioners should be careful to 
screen HD patients for ICH on non-dialysis days. 
In our study, mortality in ICH patients on HD was associated with lack of 
antihypertensive drug usage. Most patients who do not use antihypertensive drugs are 
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patients with absent or mild hypertension, although there may be some cases of drug 
withdrawal in patients with severe hypertension. Interestingly, previous studies regarding risk 
factors for poor outcomes in non-traumatic ICH also did not contain a history of hypertension 
[3, 6]. For instance, one of these studies suggests that the factors independently associated 
with 30-day mortality are GCS scores, age ≥80 years, infratentorial origin of ICH, ICH 
volume and the presence of IVH [6]. In this previous study, the incidence of hypertension in 
the poor outcome group (43%) was lower than that in the other ICH group (73%) [6], similar 
to the present results. We speculate that severe ICH depends upon factors other than 
hypertension (such as existence of microaneurysms). Hence, the occurrence of severe ICH 
in both HD and non-HD patients should be considered independently of hypertension. 
In conclusion, multivariate logistic analysis showed that hematoma location, use of 
antihypertensive drugs, use of antiplatelets/anticoagulants, and patient outcome were 
significantly different between HD and non-HD groups. On the other hand, use of 
antihypertensive drugs or antiplatelets/anticoagulants did not worsen the outcome of the ICH 
patients on HD. Thus, in HD patients, the possibility of severe ICH should be considered 
regardless of the use of antihypertensive drugs or antiplatelets/anticoagulants. In this study, 
ICH frequently occurred before the HD procedure on an HD day or on an interval day.  
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Figure legends 
 
Figure 1. Modified Rankin Scale scores in intracerebral hemorrhage (ICH) patients on 
admission and on discharge 
 
Figure 2 Relationship between ICH occurrence and the timing of the hemodialysis (HD) 
procedure. Black and white bars indicate the frequencies of living and deceased patients, 
respectively.   
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Fig. 1
Fig. 2
 Table 1: Characteristics of ICH patients (n=366) 
 HD Non-HD Logistic analysis (p value, Exp) 
 (n=32) (n=334) Univariate Multivariate 
Background 
Median age (years) 64 (28-84) 69 (8-95) (> 0.1, Student t) 
Age (≤65 years) 16 50% 134 40% 0.2801 (1.493) - - 
Gender (Female) 16 50% 135 40% 0.2952 (1.474) - - 
Use of AHD (Y) 23 72% 108 32% 0.0001 5.348 0.0009 4.934 
Use of ADD (Y) 13 41% 66 20% 0.0080 2.778 0.1880 (1.846) 
Use of AP/AC (Y) 13 41% 58 17% 0.0023 3.256 0.0068 3.299 
One drug / Two drugs 9 / 4 45 / 13  
After ICH 
Location (BG) 27 84% 192 57% 0.0055 3.994 0.0087 4.130 
BG (putamen, thalamus)/ Lobar (subcortical) 
/ Others (cerebellum, brainstem) 
27 / 3 / 2 192 / 70 / 72  
Laterality (Left sided) 18 58% 166 56% 0.4800 (1.300) - - 
Presence of IVH 17 53% 114 34% 0.0357 2.187 0.7968 (1.127) 
Operation (Y) 10 31% 70 21% 0.2128 (1.654) - - 
Surgical hematoma evacuation / Hematoma 
drain placement in the lateral ventricle 
8 / 2 45 / 25   
Patient Outcome 
Outcome (mRS) (VI) 14 44% 71 21% 0.0054 2.881 0.3150 (1.741) 
(V+VI) 22 69% 122 37% 0.0008 3.823 0.0093 4.338 
I / II / III / IV / V / VI  2 /5 /0 /3 /8 /14 51/92/22/47/51/71  
ADD, anti-diabetic drugs; AHD, anti-hypertensive drugs; AP/AC, antiplatelets or anticoagulants; BG, Basal 
ganglia; HD, hemodialysis; ICH, intracerebral hemorrhage; IVH, intraventricular hemorrhage; mRS, modified 
Rankin scale; Y, yes  
1 
 
 Table 2: Characteristics of ICH patients with HD (n=32) 
 
Dead 
(n=14) 
Alive 
(n=18) 
Logistic analysis (p value, Exp) 
Univariate Multivariate 
Background 
Age (years) 70.3+/-10.2 62.1+/-12.7 (0.0591, Student t)  
Age >65 years 64% 39% 0.1590 (2.825)   
Gender (Female) 57% 44% 0.4773 (1.667)   
HD duration until ICH (years) 7.1 +/- 5.4 7.7 +/- 4.3 (>0.1, Student t)  
HD duration < 7.5 years 62% 47% 0.4331 1.828   
Use of AHD (N) 50% 11% 0.0240 8.000 0.9864 - 
Use of ADD (N) 64% 56% 0.6185 (1.441)   
Use of AP/AC (N) 64% 56% 0.6185 (1.441)   
After ICH 
GCS on admission (median) 4 13.5 (0.0001, MWU)  
GCS <8 (Y) 93% 17% 0.0006 65.00 0.9480 - 
mRS on admission (median) 5 5 (0.0356, MWU)  
mRS = 5 93% 61% 0.0649 8.273 0.9999  
sBP (mmHg) 179.8+/- 59.8 185.0+/- 35.0 (>0.1, Student t)  
sBP <180 38% 38% 0.9577 (1.042)   
ICH location (BG) 86% 78% 0.5709 (1.714)   
ICH laterality (non-left sided) 54% 33% 0.2578 (2.333)   
ICH volume 74.3+/-16.4 24.0+/-6.2 (0.0027, Student t)  
Volume >50 ml (Y) 58% 17% 0.0240 6.993 0.9612 - 
Presence of IVH (Y) 79% 33% 0.0152 7.353 0.9856 - 
Operation (N) 86% 56% 0.0810 4.808 0.9496 - 
Patient Outcome 
GOS (median) 5 3 (0.0001, MWU)  
mRS (median) 6 4 (0.0001, MWU)  
1 
 
ADD, anti-diabetic drugs; AHD, anti-hypertensive drugs; AP/AC, anti-platelets or anti-coagulants; BG, basal 
ganglia; GCS, Glasgow Come Scale; GOS, Glasgow Outcome Scale; ICH, intracerebral hemorrhage; IVH, 
intraventricular hemorrhage; mRS, modified Rankin scale; MWU, Mann-Whitney U test; N, no; sBP, Systolic 
Blood pressure on admission; Y, yes. 
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